Supplement issueThrombogenicity of Prothrombin Complex Concentrates
Section snippets
Incidence and Clinical Spectrum
In 1973, a Task Force of the ICTH was established to investigate these adverse effects. In the first report on thromboembolic complications after PCC, 20 patients with liver disease were mentioned; 18 developed disseminated intravascular coagulation (DIC) and two patients developed pulmonary embolism. Complications after surgery were reported in 12 hemophilia B patients; pulmonary embolism was observed in six patients, thrombosis or phlebitis in three, and in addition one case each of
Risk Factors
Based on the above-mentioned reports, animal experiments, and in vitro data, it seems reasonable to postulate three major variables determining the risk of thrombogenicity: (a) predisposing factors, (b) therapy factors, and (c) quality of the PCC used.
Predisposing factors may be divided into the patient's underlying disease and the current clinical condition. It should be stressed that thromboembolic events occur even in the most severe inherited bleeding disorders after administration of PCCs,
References (33)
- et al.
Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor
Am J Med
(1988) - et al.
Effects of Trasylol on fibrin deposition and elimination in the lung of rats with intravascular coagulation induced by thrombin or thromboplastin
Thromb Res
(1974) - et al.
Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin
J Cardiothorac Anesth
(1990) - et al.
Disseminated intravascular coagulation after administration of Aprotinin in combination with deep hypothermic circulatory arrest
Am J Cardiol
(1993) - et al.
Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest
Ann Thorac Surg
(1993) - et al.
Intraoperative coronary thrombosisCan aprotinin and protamine be incriminated?
J Cardiothorac Vasc Anesth
(1994) - et al.
Activated factor VIIPresence in factor IX concentrates and persistence in the circulation after infusion
Blood
(1979) - et al.
Prothrombin complex concentratesPotentially thrombogenic materials and clues to the mechanism of thrombosis in vivo
Blood
(1977) - et al.
The coagulant active phospholipid is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits
Blood
(1982) - et al.
Comparison of different prothrombin complex concentratesIn vitro and in vivo studies
Thromb Res
(1990)
Preliminary clinical trials with barium sulfate eluate
Vox Sang
Preparation of barium sulfate eluate of plasma for physiological studies in humans
Vox Sang
Clinical use of human prothrombin complexes
N Engl J Med
Postoperative thromboses in hemophilia B [Letter]
N Engl J Med
Thromboembolic complications—Task Force report
Thrombos Diathes Haemorrh
Thromboembolische Komplikationen und Verbrauchskoagulopathien als Nebenwirkung der Substitutionstherapie (insbesondere mit Prothrombin-komplex-Präparaten)
Cited by (156)
Detection and differentiation of active and inactive isoforms of coagulation factors II, VII, IX, and X in prothrombin complex concentrate by mass spectrometry
2022, Journal of Pharmaceutical and Biomedical AnalysisCoagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment
2021, Blood ReviewsCitation Excerpt :To be noted, however, is the lack of some coagulation factors, e.g. factor V, in factor concentrates and that in DIC there is typically a deficit of all coagulation factors. The previous perception that small traces of activated coagulation factors in prothrombin complex concentrates potentially may worsen the coagulopathy, does not seem to apply significantly to current-generation concentrates [82]. When deficits concern specific coagulation factors, there are certain purified products that can be used to correct deficiencies, e.g. fibrinogen [83].
Factor VII and thromboembolism
2018, Trends in Anaesthesia and Critical CareIntraoperative Blood and Coagulation Factor Replacement During Neurosurgery
2018, Neurosurgery Clinics of North America